Chuanyang Liu

Dr. Chuanyang Liu

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2020 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
CZChu‐Shu Zhu
Chu‐Shu Zhu
CLChuanyang Liu
Chuanyang Liu
XQXinyuan Qiu
Xinyuan Qiu
SXSi‐Si Xie
Si‐Si Xie
WLWen‐Ying Li
Wen‐Ying Li
LZLv-yun Zhu
Lv-yun Zhu

29 May 2022 in Phytomedicine
Verified
Journal Article
Closed access
YGYiqing Gu
Yiqing Gu
SDShuni Duan
Shuni Duan
MDMingning Ding
Mingning Ding
QZQi Zheng
Qi Zheng
GFGuifang Fan
Guifang Fan
RLRunping Liu
Runping Liu

1 January 2019 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
CZChu-Shu Zhu
Chu-Shu Zhu
LZLingyun Zhu
Lingyun Zhu
DTDe-An Tan
De-An Tan
XQXinyuan Qiu
Xinyuan Qiu
CLChuanyang Liu
Chuanyang Liu
LZLv-yun Zhu
Lv-yun Zhu
Over the decades, the biological role of microRNAs (miRNAs) in the post-transcriptional regulation of gene expression has been discovered in many cancer types, thus initiating the tremendous expectation of their application as biomarkers in the diagnosis, prognosis, and treatment of cancer. Hence, the development of efficient miRNA detection methods in vitro is in high demand. Extensive efforts have been made based on the intrinsic properties of miRNAs, such as low expression levels, high sequence homology, and short length, to develop novel in vitro miRNA detection methods with high accuracy, low cost, practicality, and multiplexity at point-of-care settings. In this review, we mainly summarized the newly developed in vitro miRNA detection methods classified by three key elements, including biological recognition elements, additional micro-/nano-materials and signal transduction/readout elements, their current challenges and further applications are also discussed.

23 October 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
CLChuanyang Liu
Chuanyang Liu
LMLu Min
Lu Min
JKJingyu Kuang
Jingyu Kuang
CZChushu Zhu
Chushu Zhu
XQXinyuan Qiu
Xinyuan Qiu
LZLingyun Zhu
Lingyun Zhu
Breast cancer is the leading cause of cancer-associated deaths among females. In recent decades, microRNAs (miRNAs), a type of short non-coding RNA that regulates gene expression at the post-transcription level, have been reported to participate in the regulation of many hub genes associated with tumorigenesis, tumor progression, and metastasis. However, the precise mechanism by which miRNAs regulate breast cancer metastasis remains poorly discussed, which limits the opportunity for the development of novel, effective therapeutic targets. Here, we aimed to determine the miR-622-related principal regulatory mechanism in cancer. First, we found that miR-622 was significantly related to a poor prognosis in various cancers. By utilizing an integrated miRNA prediction process, we identified 77 promising targets and constructed a protein-protein interaction network. Furthermore, enrichment analyses, including GO and KEGG pathway analyses, were performed to determine the potential function of miR-622, which revealed regulation networks and potential functions of miR-622. Then, we identified a key cluster comprised of six hub genes in the protein-protein interaction network. These genes were further chosen for pan-cancer expression, prognostic and predictive marker analyses based on the TCGA and GEO datasets to mine the potential clinical values of these hub genes. To further validate our bioinformatic results, the regulatory axis of miR-622 and RNF8, one of the hub genes recently reported to promote breast cancer cell EMT process and breast cancer metastasis, was selected as in vitro proof of concept. In vitro, we demonstrated the direct regulation of RNF8 by miR-622 and found that the predicted miR-622-RNF8 axis could regulate RNF8-induced epithelial-mesenchymal transition, cell migration, and cell viability. These results were further demonstrated with rescue experiments. We established a closed-loop miRNA-target-phenotype research model that integrated the bioinformatic analysis of the miRNA target genes and experimental validation of the identified key miRNA-target-phenotype axis. We not only identified the hub target genes of miR-622 in silico but also revealed the regulatory mechanism of miR-622 in breast cancer cell EMT process, viability, and migration in vitro for the first time.

28 September 2022 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
TZTianyi Zhang
Tianyi Zhang
CLChuanyang Liu
Chuanyang Liu
WLWenying Li
Wenying Li
JKJingyu Kuang
Jingyu Kuang
XQXin-Yuan Qiu
Xin-Yuan Qiu
LZLingyun Zhu
Lingyun Zhu
In the eukaryotic cellular milieu, proteins are continuously synthesized and degraded effectively via endogenous protein degradation machineries such as the ubiquitin–proteasome and lysosome pathways. By reengineering and repurposing these natural protein regulatory mechanisms, the targeted protein degradation (TPD) strategies are presenting biologists with powerful tools to manipulate the abundance of proteins of interest directly, precisely, and reversibly at the post-translational level. In recent years, TPD is gaining massive attention and is recognized as a paradigm shift both in basic research, application-oriented synthetic biology, and pioneering clinical work. In this review, we summarize the updated information, especially the engineering efforts and developmental route, of current state-of-the-art TPD technology such as Trim-Away, LYTACs, and AUTACs. Besides, the general design principle, benefits, problems, and opportunities to be addressed were further analyzed, with the aim of providing guidelines for exploration, discovery, and further application of novel TPD tools in the future.

1 November 2020 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
JKJingyu Kuang
Jingyu Kuang
LMLu Min
Lu Min
CLChuanyang Liu
Chuanyang Liu
SCSi Chen
Si Chen
CGChangsong Gao
Changsong Gao
LZLingyun Zhu
Lingyun Zhu
RNF8 (ring finger protein 8), a RING finger E3 ligase best characterized for its role in DNA repair and sperm formation via ubiquitination, has been found to promote tumor metastasis in breast cancer recently. However, whether RNF8 also plays a role in other types of cancer, especially in lung cancer, remains unknown. We show here that RNF8 expression levels are markedly increased in human lung cancer tissues and negatively correlated with the survival time of patients. Overexpression of RNF8 promotes the EMT process and migration ability of lung cancer cells, while knockdown of RNF8 demonstrates the opposite effects. In addition, overexpression of RNF8 activates the PI3K/Akt signaling pathway, knockdown of RNF8 by siRNA inhibits this activation, and pharmacologic inhibition of PI3K/Akt in RNF8-overexpressing cells also reduces the expression of EMT markers and the ability of migration. Furthermore, RNF8 is found to directly interact with Slug and promoted the K63-Ub of Slug, and knockdown of Slug disrupts RNF8-dependent EMT in A549 cells, whereas overexpression of Slug rescues RNF8-dependent MET in H1299 cells, and depletion of RNF8 expression by shRNA inhibits metastasis of lung cancer cells in vivo. Taken together, these results indicate that RNF8 is a key regulator of EMT process in lung cancer and suggest that inhibition of RNF8 could be a useful strategy for lung cancer treatment. Implications: This study provides a new mechanistic insight into the novel role of RNF8 and identifies RNF8 as a potential new therapeutic target for the treatment of lung cancer.